search query: @indexterm PHARMACEUTICAL INDUSTRY / total: 673
references: 51-60 / 673
« previous page | next page »
 titleyearauthor
51.
Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules
International Journal of Research in Marketing
2008 : DEC, VOL. 25:4, p. 247-260
 2008 Gonzalez, J. (et al.)
52.
Generalizations on the effectiveness of pharmaceutical promotional expenditures
International Journal of Research in Marketing
2008 : DEC, VOL. 25:4, p. 234-246
 2008 Kremer, S.T.M. (et al.)
53.
Health and marketing: The emergence of a new field of research
International Journal of Research in Marketing
2008 : DEC, VOL. 25:4, p. 229-233
 2008 Stremersch, S.
54.
The evolution of the phar maceutical-biotechnology industry
Business history
2008 : SEP, VOL. 50:5, p. 583-601
 2008 Gottinger, H-W.
Umali, C.L.
55.
The ethical aspects of direct to consumer advertising of prescription drugs in the United Kingdom: physician versus consumer views
Journal of Advertising Research
2008 : SEP, VOL 48:3 p. 450-464
 2008 Reast, J.
Palihawadana, D.
Shabbir, H.
56.
Heedful interrelating, knowledge sharing, and new drug development
Journal of Knowledge Management
2008 : VOL. 12:3, p. 127-140
 2008 Styhre, A. (et al.)
57.
Direct-to-consumer advertising and its effect on prescription requests
Journal of Advertising Research
2008 : MAR, VOL. 48:1, p. 42-56
 2008 Hausman, A.
58.
Public responses to direct-to-consumer advertising of prescription drugs
Journal of Advertising Research
2008 : MAR, VOL. 48:1, p. 30-41
 2008 Yuan, S.
59.
Stakeholder theory: antidote to a drug company's market health? A case study of Synthroid
Journal of communication management
2008 : VOL. 12:1, p. 5-17
 2008 Plowman, K.D.
Ostrom-Blonigen, J.
Bornsen, S.
60.
Performance effects of imitative entry
Strategic Management Journal
2008 : AUG, VOL. 29:8, p. 797-817
 2008 Ethiraj, S.K.
Zhu, D.H.
« previous page | next page »
SCIMA